Literature DB >> 10828026

Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG.

A Moreau1, S Lacroix-Desmazes, N Stieltjes, E Saenko, S V Kaveri, R D'Oiron, Y Sultan, D Scandella, M D Kazatchkine.   

Abstract

We have analyzed the properties of anti-factor VIII (FVIII) immunoglobulin (Ig) G recovered by affinity chromatography on FVIII-Sepharose from the IgG fraction of the plasma of healthy individuals and nonresponder patients with hemophilia A. Affinity-purified anti-FVIII antibodies were found to neutralize FVIII activity and to bind to FVIII with an affinity similar to that of anti-FVIII IgG that had been affinity-purified from the plasma of inhibitor-positive hemophilia patients and of patients with anti-FVIII autoimmune disease. The antibodies also exhibited patterns of reactivity with thrombin-digested FVIII similar to those of FVIII inhibitors and preferentially recognized epitopes located in the light chain of FVIII. These observations suggest that FVIII inhibitors occurring in hemophilia A and in patients with anti-FVIII autoimmune disease originate from the expansion of preexisting natural anti-FVIII clones that exhibit FVIII-neutralizing properties.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828026

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Authors:  Johannes Oldenburg; Sébastien Lacroix-Desmazes; David Lillicrap
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

2.  Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Authors:  Y Dargaud; A Pavlova; S Lacroix-Desmazes; K Fischer; M Soucie; S Claeyssens; D W Scott; R d'Oiron; G Lavigne-Lissalde; G Kenet; C Escuriola Ettingshausen; A Borel-Derlon; T Lambert; G Pasta; C Négrier
Journal:  Haemophilia       Date:  2016-01       Impact factor: 4.287

3.  Designed ankyrin repeat proteins: a new approach to mimic complex antigens for diagnostic purposes?

Authors:  Stefanie Hausammann; Monique Vogel; Johanna A Kremer Hovinga; Sebastien Lacroix-Desmazes; Beda M Stadler; Michael P Horn
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

4.  Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A.

Authors:  Sandrine Delignat; Jules Russick; Bagirath Gangadharan; Julie Rayes; Mathieu Ing; Jan Voorberg; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2018-12-13       Impact factor: 9.941

Review 5.  Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

Authors:  Aditi Varthaman; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

Review 6.  Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1.

Authors:  Davide Matino; Sajjad Afraz; George Zhao; Paul Tieu; Marco Gargaro; Francesca Fallarino; Alfonso Iorio
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

Review 7.  Antiphospholipid antibodies: paradigm in transition.

Authors:  Lawrence L Horstman; Wenche Jy; Carlos J Bidot; Yeon S Ahn; Roger E Kelley; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; Seyed Ali Mousavi; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2009-01-20       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.